Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Compared to other common HIV treatments, dolutegravir-based regimens maintained viral suppression even without perfect adherence.
Two-drug combo of dolutegravir and lamivudine suppresses HIV in newly diagnosed people.
The small single-site study will need to be replicated in a larger group of adolescents.
Many participants on two-drug regimens had more treatment under their belt and more chronic conditions.
However, all integrase inhibitors were associated with similar weight gain.
People whose viral load rebounds on Tivicay may not need to switch medications.
ViiV’s two-drug Dovato also boasted a high genetic barrier to the development of viral resistance.
The single-tablet regimen is now approved for previously treated people with an undetectable viral load.
A high success rate was seen halfway into a 48-week study in which people with HIV started treatment within two weeks of diagnosis.
A recent small study examined pairings of antiretrovirals and statins or blood pressure medications.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
Researchers at George Washington University take a look.
The latest revision recognizes the importance of treatment as prevention.
Here are the HIV treatment news stories with the most views this year.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.